2Naji F, Suran D, Kanic V, et al. Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardio- version [ J ]. Med Sci Monit,2009,15 ( 9 ) : CR494 - 498.
3Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence result of atrial fibrillation after electrical cardiovcrsion J ]. Am J Cardiol,2006,97 ( 10 ) :1490 -1493.
4Naji F, Suran D, Kanie V, et al. Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after suceessful card- ioversion[ J]. Int Heart J,2009,50(2) : 153 - 160.
5Tveit A, Grundtving M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after cardioversion [ J ]. Am J Cardiol,2004,93(6) :780 -782.
6Almroth H, Hoglund N, Boman K, et al. Atorvastatin and persistent atrial fibrillation following cardioversion:a randomized placebo-con- trolled multicentre study [ J ]. Eur Heart J,2009,30 (7) : 827 - 833.
7Chung MK, Martin DO,Spreeher D, et al. C-reactive protein eleva- tion in patients with atrial arrhythmias:inflammatory mechanisms and persistence of atrial fibrillation [ J ]. Circulation, 2001,104 (24) :2886 -2891.
2Pstay BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation, 1997,96:2455-2461.
3Kannel WB, Wolf PA Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol ,1998,82:2N-9N.
4Jouven X, Desnos M, Guerot C, et al. Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study Ⅰ. Eur Heart J, 1999,20:896-899.
5Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med, 2002,347:1825-1833.
6Hagens VE, Ranchor AV, Van Sonderen E,et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol,2004,43:241-247.
7Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation,2001,104:2118-2150.
8Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation,1999, 100 :376-380.
9Wachtell K, Letho M, Gerdts E, et al. Angiotensin Ⅱ receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol,2005,45:712-719.
2Korcmtzopoulos P , Kolettis TM , Galctris D, et al. The role of oxidctive stress in the potthogenesis cmd perpetuation of atriotl fibrillation [ J ]. International journal of cardiology, 2007,115 (2) :135-143.
